Vistagen Therapeutics VTGN
NASDAQ VTGN
$0.19 -0.01 (-5.00%)
At close: Nov 19, 2026 · 4:00 PM EST

Vistagen Therapeutics (VTGN) Share-based Compensation (2010 - 2026)

Updated

Vistagen Therapeutics' Share-based Compensation came in at $907,000 for fiscal Q2 2027 (quarter ended Sep 30, 2026), down 17.2% from $1.1 million a year earlier and down 8.5% from the prior quarter.

Analysis

Vistagen Therapeutics (VTGN) Share-based Compensation (2010 - 2026) Analysis & Trends

Over the trailing twelve months to Sep 30, 2026, Vistagen Therapeutics reported Share-based Compensation of $3.88 million, down 4.2% year-over-year; for FY2026 (ended Mar 31, 2026), it came in at $4 million, down 7.4% from FY2025.

  • Share-based Compensation carries a five-year compound annual growth rate of 11.6% (FY2021 to FY2026).
  • Going back by fiscal year, Share-based Compensation was $4.32 million in FY2025 (+97.8%), $2.18 million in FY2024 (-34.6%), $3.34 million in FY2023 (-4.2%) and $3.48 million in FY2022 (+50.9%).
  • The five-year range for quarterly Share-based Compensation is $506,700 (fiscal Q3 2024) to $1.4 million (fiscal Q4 2022).
  • Year-over-year, Share-based Compensation increased in four of the last eight quarters, with growth averaging 20.0%.
  • The fastest year-over-year change in Share-based Compensation over five years came in fiscal Q4 2022 (growth of 186.0%), and the weakest in fiscal Q4 2023 (a decline of 57.1%).
  • Business Quant data shows VTGN's Share-based Compensation at $991,000 (Q1 2027), $889,000 (Q4 2026) and $1.1 million (Q3 2026) in the three fiscal quarters before Q2 2027.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. (Qtr)
1 PetVivo Holdings 3,096.39 Bn 3,096.39 Bn 196,075.00 372,681.00
2 Eli Lilly 1,202.70 Bn 1,176.32 Bn 20.46 Bn 200.00 Mn
3 Johnson & Johnson 649.77 Bn 569.63 Bn 17.30 Bn 357.00 Mn
4 AbbVie 507.00 Bn 475.00 Bn 13.12 Bn 160.00 Mn
5 Merck 329.70 Bn 292.64 Bn 13.19 Bn 369.00 Mn
6 Novartis Ag 291.91 Bn 265.14 Bn - -
7 Amgen 236.26 Bn 187.91 Bn 7.58 Bn 128.00 Mn
8 Gilead Sciences 207.15 Bn 182.26 Bn 6.73 Bn 234.00 Mn
9 Gsk 193.54 Bn 176.38 Bn - -
10 Vistagen Therapeutics 7.34 Mn -151.60 Mn - 907,000.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 907,000.00
Jun 30, 2026 991,000.00
Mar 31, 2026 889,000.00
Dec 31, 2025 1.10 Mn
Sep 30, 2025 1.10 Mn
Jun 30, 2025 916,000.00
Mar 31, 2025 963,000.00
Dec 31, 2024 1.08 Mn
Sep 30, 2024 1.11 Mn
Jun 30, 2024 1.16 Mn
Mar 31, 2024 522,000.00
Dec 31, 2023 506,700.00
Sep 30, 2023 583,700.00
Jun 30, 2023 569,000.00
Mar 31, 2023 601,100.00
Dec 31, 2022 746,300.00
Sep 30, 2022 1.03 Mn
Jun 30, 2022 956,900.00
Mar 31, 2022 1.40 Mn
Dec 31, 2021 723,800.00
API Access

Vistagen Therapeutics Share-based Compensation API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=share-based-compensation&ticker=VTGN&period=max&api_key=YOUR_API_KEY